19 results about "Dexamethasone Sodium Phosphate" patented technology

The invention relates to compound herba houttuyniae eye drops as well as a preparation method and application of the compound herba houttuyniae eye drops. Comprising the following preparation raw materials in percentage by mass: 1-6% of a herba houttuyniae extracting solution, 1-5% of an aglaia odorata extracting solution, 1-2% of a gelidium amansii extracting solution, 0.1-0.3% of acyclovir, 0.1-0.3% of tobramycin, 0.01-0.1% of dexamethasone sodium phosphate, 0.1-1% of sodium hyaluronate, 0.1-3% of glycerol and 88-93% of purified water. According to the compound herba houttuyniae eye drops prepared by the preparation method disclosed by the invention, the herba houttuyniae extracting solution, the aglaia odorata extracting solution, the gelidium amansii extracting solution, the acyclovir, the tobramycin and the dexamethasone sodium phosphate are combined for use, so that the compound herba houttuyniae eye drops have a relatively good curative effect on pets suffering from bacterium and virus mixed infection type conjunctivitis / keratitis; the compound herba houttuyniae eye drops are good in high-temperature-resistant storage stability and good in curative effect, the problem of frequent administration can be reduced, and the compound herba houttuyniae eye drops are more convenient to use and store.

Corticosteroid compositions including a corticosteroid drug substance (e.g., fluocinolone, fluocinolone acetonide, dexamethasone, dexamethasone phosphate, dexamethasone sodium phosphate, triamcinolone, and triamcinolone acetonide) or a or a salt or derivative thereof and one or more irregular-shaped particulate fatty acid or keto-enol tautomer complexation agents admixed in a dispersal medium, having a release profile with one or more phases of drug release. These compositions are extended release corticosteroid compositions may release a clinically useful level of corticosteroid for more than 1 to 12 months within the body. Also described herein are methods of forming and methods of using these compositions.

This invention discloses a sodium alginate cross-linked matrix metalloproteinase-sensitive peptide-loaded dexamethasone sodium phosphate hydrogel and its preparation method. The dexamethasone-loaded hydrogel has good injectability. After injection, it is cleaved by MMPs at the site of inflammation in an inflammatory environment to release dexamethasone, exhibiting good sustained-release effect. It achieves targeted and long-acting treatment of inflammatory arthritis, osteoarthritis or other inflammatory diseases, and reduces the frequency of repeated intra-articular injections of glucocorticoids.

A cochlear hearing aid system for providing electrical stimulation to auditory nerve fibers of a cochlea of a recipient of the cochlear hearing aid system is disclosed. The cochlear hearing aid system comprises a microphone configured to receive an acoustical signal and provide an audio signal based on the acoustical signal; a signal processor unit configured to receive the audio signal and process the audio signal; an electrode lead including a plurality of electrodes configured to stimulate the auditory nerve fibers based on the processed audio signal, wherein the electrode lead comprises: an electrode carrier maintaining the electrode contacts and wires, wherein the electrode carrier is made of silicone and is loaded by dexamethasone; a first layer (or sub-layers) of gelatin which is coated and chemically cross-linked selectively on a silicone outer surface of the electrode lead, wherein dexamethasone sodium phosphate is embedded in the first layer (or sub-layers); and a second layer of gelatin which is coated and physically cross-linked onto the first layer.

Corticosteroid compositions including a corticosteroid drug substance (e.g., fluocinolone, fluocinolone acetonide, dexamethasone, dexamethasone phosphate, dexamethasone sodium phosphate, triamcinolone, and triamcinolone acetonide) or a or a salt or derivative thereof and one or more irregular-shaped particulate fatty acid or keto-enol tautomer complexation agents admixed in a dispersal medium, having a release profile with one or more phases of drug release. These compositions are extended release corticosteroid compositions may release a clinically useful level of corticosteroid for more than 1 to 12 months within the body. Also described herein are methods of forming and methods of using these compositions.

The invention provides the dexamethasone sodium phosphate photodegradation impurity as well as the preparation method and the detection method thereof, so that the blank in the research aspect of the dexamethasone sodium phosphate photodegradation impurity is filled, and the process research and the quality control of dexamethasone sodium phosphate raw material medicines and preparations are facilitated; the method has an important practical value for controlling the product quality of dexamethasone sodium phosphate.

A dexamethasone sodium phosphate lyophilized composition suitable for administration to the eardrum and a preparation method therefor are provided. Provided is a lyophilized powder injection preparation, wherein the preparation is a dexamethasone medicament lyophilized powder injection omitting a lyophilization supporting agent or an excipient or a matrix agent, wherein the lyophilized powder injection preparation comprises pharmaceutically acceptable auxiliary material of glycerol, and the glycerol is added before the lyophilized powder injection preparation is lyophilized. The provided lyophilized preparation omits a lyophilized supporting agent or an excipient, achieving the effect of improving the stability of the drug by only adding a small amount of glycerol, and also allowing adjustment the osmotic pressure to be closer to the physiological osmotic pressure during the tympanogram administration and prolong the action time of local administration, thereby increasing the safety and effectiveness of the tympanogram administration.

The utility model relates to the technical field of dexamethasone sodium phosphate drying, in particular to dexamethasone sodium phosphate drying equipment which comprises a drying cylinder, supporting seats, connecting columns, heating rods, stirring plates, a feeding plate, a weight sensor, a contact and an alarm, the supporting seats are arranged on the two sides of the drying cylinder, the connecting columns are arranged in the supporting seats, and the heating rods are arranged on the connecting columns. The heating rod is arranged on the outer wall of the drying cylinder, the stirring plate is arranged in the drying cylinder, and the feeding plate is arranged on the inner wall of the drying cylinder; the dexamethasone sodium phosphate crystal moves in cooperation with the stirring plate and the feeding plate, the dexamethasone sodium phosphate crystal can be conveyed to the high position under the action of the feeding plate when conveyed to one end of the drying cylinder, the dexamethasone sodium phosphate crystal falls above the weight sensor, and when the dexamethasone sodium phosphate crystal is not fully dried, the dexamethasone sodium phosphate crystal is conveyed to the high position under the action of the feeding plate. When the dexamethasone sodium phosphate crystal is dried, the weight sensor can be triggered to turn over, and the dexamethasone sodium phosphate crystal in the drying cylinder can be dried again.

The invention relates to the field of medical application of biological hydrogel, in particular to dexamethasone loaded hydrogel delivered across tympanic membranes and a preparation method of the dexamethasone loaded hydrogel, the hydrogel takes gelatin Gel and dopamine modified hyaluronic acid HADA as base materials, a three-dimensional network structure is formed through enzymatic crosslinking of transglutaminase mTGase, dexamethasone sodium phosphate Dex is loaded, and the hydrogel can be used for preparing the dexamethasone loaded hydrogel. Furthermore, local trans-tympanic membrane middle ear drug delivery and release are realized; specifically, a solution A composed of Gel, HADA and Dex and a solution B composed of mTGase are evenly mixed according to the volume ratio of 4: 1 and dropwise added to the surface of the tympanic membrane through an external auditory canal, and finally Gel-HADA-Dex hydrogel is formed on the surface of the tympanic membrane. Local precise high-concentration drug delivery can be achieved, systemic drug toxicity is avoided, materials are safe, ear toxicity is avoided, meanwhile, adhesion performance is high, drug release is continuous, gradual self-degradation is achieved, manual taking out is not needed, and use convenience is remarkably improved.

According to the technical scheme, the automatic preparation device is characterized by comprising a base, a preparation barrel is fixedly installed on the top face of the base, and a PLC is fixedly installed on the outer circle wall face of the preparation barrel; the heating assembly is arranged on the top surface of the preparation barrel and is used for heating the eye drop stock solution, the heating assembly comprises a mounting hole, the mounting hole is formed in the top surface of the preparation barrel, a servo motor is fixedly mounted on the top surface of the preparation barrel, a driving shaft of the servo motor is movably connected with the mounting hole in a sleeving manner, and the driving shaft of the servo motor is connected with the mounting hole in a sleeving manner. A connecting column is fixedly mounted on the bottom surface of a driving shaft of the servo motor, and the base, the preparation barrel, the PLC, the mounting hole, the servo motor, the connecting column, a rotating column, a stirring plate, a fixing pipe, a supporting column, a heating groove and a heating rod are arranged to be used in cooperation, so that heating is started from the center of an eye drop stock solution at high temperature; therefore, the eye drops can be conveniently heated and prepared.

The invention relates to an inducer and an induction method for adipose differentiation of mesenchymal stem cells, and the inducer for adipose differentiation of mesenchymal stem cells is characterized in that 3-isobutyl-1-methylxanthine IBMX, insulin, indometacin, fetal calf serum, dexamethasone sodium phosphate, astragaloside, resveratrol and iridoside A are contained in a DMEM (dulbecco's modified eagle medium) high glucose culture medium. When the mesenchymal stem cells are cultured, only the inducer is used, and different proportions of inducers do not need to be added into a culture medium like the prior art; moreover, the adipose differentiation induction time is shortened, the adipose differentiation induction rate is not lower than 91.3% after culture is carried out for 15 days, and the adipose differentiation induction rate is not lower than 94.8% after culture is carried out for 21 days.

The invention relates to the field of medicines, in particular to a crystal form of dexamethasone sodium phosphate as well as a preparation method and application thereof. The crystal form provided by the invention is different from the existing known dexamethasone sodium phosphate crystal form, has distinct outlines, can be perfectly reproduced, shows good characteristics in the aspects of placing stability and solution clarity of subsequent finished products, and has wide application prospects in pharmaceutical development of dexamethasone sodium phosphate. The preparation method provided by the invention is simple and easy to operate, stable in process, green, environment-friendly and low in production cost, solves the problems of stability and dissolution clarity of the dexamethasone sodium phosphate, is suitable for industrial production of the dexamethasone sodium phosphate, improves the production efficiency and is beneficial to technical popularization.

The invention provides temperature-controlled drug-loading hydrogel and a preparation method and application thereof, the temperature-controlled drug-loading hydrogel comprises Dexp-coated PLGA and temperature-sensitive hydrogel, and the mass volume ratio of the Dexp-coated PLGA to the temperature-sensitive hydrogel is (10-50) mg: 1 mL; the Dexp-coated PLGA is a PLGA microsphere loaded with dexamethasone sodium phosphate, and the temperature-sensitive hydrogel is prepared from poloxamer and polycarbophil. Poloxamer and polycarbophil are adopted as temperature-sensitive hydrogel, and matched with Dexp-PLGA composed of dexamethasone sodium phosphate (Dexp) entrapped by PLGA microspheres to form temperature-control drug-loading hydrogel (Dexp-PLGA-Gel), the temperature-control drug-loading hydrogel can be automatically degraded, is not left in vivo, reduces toxic and side effects, is in a liquid state at the temperature of 4 DEG C or normal temperature, is in a gel state at the body temperature of 36 DEG C, and is free of toxic and side effects. The medicine can stay in the middle ear for a long time to play a role, the injection frequency is reduced, and the pain of a patient is relieved.

The present disclosure is directed to treating patients with Ataxia-Telangiectasia by administering to the subject at least 5 mg of dexamethasone sodium phosphate (DSP) that has been loaded into erythrocytes. Also disclosed herein are methods of treating a pediatric subject with Ataxia-Telangiectasia who is between 9 and 15 kilograms in weight.

The invention discloses a dexamethasone sodium phosphate freeze-dried composition suitable for ear drum administration and a preparation method of the dexamethasone sodium phosphate freeze-dried composition. The invention provides a freeze-dried powder injection preparation, the preparation is a dexamethasone drug freeze-dried powder injection, does not contain a freeze-drying supporting agent or an excipient or a support agent, the freeze-dried powder injection preparation contains a pharmaceutically acceptable auxiliary material glycerol, and the glycerol is added before the freeze-dried powder injection preparation is freeze-dried. The provided freeze-drying preparation does not contain a freeze-drying supporting agent or an excipient, the effect of improving the stability of the medicine can be achieved only by adding a small amount of glycerol before the preparation is freeze-dried, meanwhile, the osmotic pressure can be adjusted, so that the osmotic pressure is closer to physiological osmotic pressure during tympanic administration, and the action time of local administration is prolonged; and the safety and effectiveness of tympanic administration are improved.

The present application belongs to the field of biological medicine, and relates to a dexamethasone sodium phosphate lyophilized composition suitable for tympanic administration and a preparation method thereof. The present application provides a lyophilized powder injection preparation, which is a dexamethasone lyophilized powder injection, does not contain a lyophilized support agent or an excipient or a support agent, and contains a pharmaceutically acceptable auxiliary material glycerol, wherein the glycerol is added before lyophilization of the lyophilized powder injection preparation. The lyophilized preparation provided by the present application does not contain a lyophilized support agent or an excipient, and only a small amount of glycerol is added before lyophilization of the preparation to achieve the effect of improving the stability of the drug. Meanwhile, the osmotic pressure can be adjusted to be closer to the physiological osmotic pressure during tympanic administration, the local administration time is prolonged, the safety and effectiveness of tympanic administration are increased.

The present disclosure is directed to treating patients with Ataxia-Telangiectasia by administering to the subject at least 5 mg of dexamethasone sodium phosphate (DSP) that has been loaded into erythrocytes. Also disclosed herein are methods of treating a pediatric subject with Ataxia-Telangiectasia who is between 9 and 15 kilograms in weight.

The application relates to a preparation method and application of a drug-loaded copper sulfide polyethylene glycol hydrogel composite polycaprolactone support. The preparation method comprises the following steps: mixing dexamethasone sodium phosphate Dexp, copper sulfide nanoparticles CuS NPs and a tris-hydroxymethyl aminomethane hydrochloride Tris-HCl solution with pH=8.5 under light-proof conditions to obtain drug-loaded copper sulfide nanoparticles D-CuS NPs; in a 1xPBS medium containing triethanolamine, the D-CuS NPs are doped into a four-arm-polyethylene glycol-mercapto polymer network for crosslinking to obtain drug-loaded copper sulfide polyethylene glycol D-CuS-PEG hydrogel; a polycaprolactone PCL support is obtained through 3D printing; the D-CuS-PEG hydrogel is coated on the surface of the PCL support through an immersion coating method, and the D-CuS-PEG hydrogel is completely gelled to obtain a drug-loaded copper sulfide polyethylene glycol hydrogel composite polycaprolactone D-CuS-PEG-PCL support.